}}</ref><ref name="pmid19179855">{{cite journal |vauthors=Marona-Lewicka D, Nichols DE |title=WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation |journal=Behav Pharmacol |volume=20 |issue=1 |pages=114–8 |year=2009 |pmid=19179855 |doi=10.1097/FBP.0b013e3283242f1a |url=}}</ref> It is sometimes referred to as a [[silent antagonist]] at the former receptor.<ref>{{Cite journal | author = A. Fletcher, E. A. Forster, D. J. Bill, G. Brown, I. A. Cliffe, J. E. Hartley, D. E. Jones, A. McLenachan, K. J. Stanhope, D. J. Critchley, K. J. Childs, V. C. Middlefell, L. Lanfumey, R. Corradetti, A. M. Laporte, H. Gozlan, M. Hamon & C. T. Dourish | title = Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist | journal = [[Behavioural Brain Research]] | volume = 73 | issue = 1–2 | pages = 337–53| year = 1996 | pmid = 8788530 | doi = 10.1016/0166-4328(96)00118-0 }}</ref> It is closely related to [[WAY-100,135]].

 
}}</ref><ref  name="ParseyR2002Effects">{{Cite journal

 
|author1=R. V. Parsey |author2=M. A. Oquendo |author3=N. R. Simpson |author4=R. T. Ogden |author5=R. Van Heertum |author6=V. Arango V |author7=J. J. Mann | title  = Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635

 
| <ref name="ParseyR2002Effects"/>

 
| <ref name="ParseyR2002Effects"/>

 
| <ref name="ParseyR2002Effects"/>

 
|author1=Peter A. Sargent |author2=Karen Husted Kjaer |author3=Christopher J. Bench |author4=Eugenii A. Rabiner |author5=Cristina Messa |author6=Jeff Meyer |author7=Roger N. Gunn |author8=Paul M. Grasby |author9=Philip J. Cowen | title = Brain Serotonin<sub>1A</sub> Receptor Binding Measured by Positron Emission Tomography With [<sup>11</sup>C]WAY-100635. Effects of Depression and Antidepressant Treatment

 
WAY-100,635 has also been found to increase the analgesic effects of [[opioid]] drugs in a dose-dependent manner, in contrast to 5-HT<sub>1A</sub> agonists such as [[8-OH-DPAT]] which were found to reduce opioid analgesia.<ref name="pmid15109976">{{cite journal |vauthors=Bardin L, Colpaert FC |title=Role of spinal 5-HT(1A) receptors in morphine analgesia and tolerance in rats |journal=European Journal of Pain |volume=8 |issue=3 |pages=253–61 |date=June 2004 |pmid=15109976 |doi=10.1016/j.ejpain.2003.09.002 |url=}}</ref><ref name="pmid17393145">{{cite journal |vauthors=Berrocoso E, De Benito MD, Mico JA |title=Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats |journal=Psychopharmacology |volume=193 |issue=1 |pages=97–105 |date=July 2007 |pmid=17393145 |doi=10.1007/s00213-007-0761-8 |url=}}</ref> However, since 5-HT<sub>1A</sub> agonists were also found to reduce opioid-induced [[respiratory depression]] and WAY-100,635 was found to block this effect,<ref name="pmid10640309">{{cite journal |vauthors=Sahibzada N, Ferreira M, Wasserman AM, Taveira-DaSilva AM, Gillis RA |title=Reversal of morphine-induced apnea in the anesthetized rat by drugs that activate 5-hydroxytryptamine(1A) receptors |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=292 |issue=2 |pages=704–13 |date=February 2000 |pmid=10640309 |doi= |url=}}</ref> it is likely that 5-HT<sub>1A</sub> antagonists might worsen this side effect of opioids. Paradoxically, chronic administration of the very high efficacy 5-HT<sub>1A</sub> agonist [[befiradol]] results in potent analgesia following an initial period of [[hyperalgesia]], an effect most likely linked to desensitisation and/or downregulation of 5-HT<sub>1A</sub> receptors (i.e. analogous to a 5-HT<sub>1A</sub> antagonist-like effect).<ref name="pmid15528450">{{cite journal |vauthors=Bardin L, Assié MB, Pélissou M, Royer-Urios I, Newman-Tancredi A, Ribet JP, Sautel F, Koek W, Colpaert FC |title=Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-<nowiki/>{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=312 |issue=3 |pages=1034–42 |date=March 2005 |month= |pmid=15528450 |doi=10.1124/jpet.104.077669 |url=}}</ref><ref name="pmid16921393">{{cite journal |vauthors=Assié MB, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A |title=Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat |journal=British Journal of Pharmacology |volume=149 |issue=2 |pages=170–8 |date=September 2006 |pmid=16921393 |pmc=2013794 |doi=10.1038/sj.bjp.0706859 |url=}}</ref><ref name="pmid18809418">{{cite journal |vauthors=Buritova J, Berrichon G, Cathala C, Colpaert F, Cussac D |title=Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study |journal=Neuropharmacology |volume=56 |issue=2 |pages=350–61 |date=February 2009 |pmid=18809418 |doi=10.1016/j.neuropharm.2008.09.004 |url=}}</ref>
